---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Limitations of current therapies"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Limitations of current therapies. Topics: Progression on available treatments, Cross-resistance between androgen receptor pathway inhibitors, Radiographic progression-free survival with a change in ARPI, Use of sequential ARPI therapy in place of chemotherapy, and 6 further topics. 11 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Limitations of current therapies

<a id="heading-2.2.2.1.10"></a>

## 2.2.2.1.10 Limitations of Current Therapies

<a id="topic-2.2.2.1.10-1"></a>

### Summary

- All patients treated for mCRPC eventually progress. The EAU guideline advises avoiding sequencing of androgen receptor-targeted agents, citing cross-resistance that it extends from abiraterone to apalutamide and darolutamide.
- Activity of a second ARPI is limited. In a randomized crossover trial, PSA responses to second-line therapy occurred in 26 of 73 participants (36%) receiving enzalutamide and 3 of 75 (4%) receiving abiraterone. In a single-arm study of enzalutamide after at least 24 weeks of abiraterone, median radiographic progression-free survival (rPFS) was 8.1 months and the unconfirmed PSA response rate was 27% (48 of 181). In PLATO, adding abiraterone after PSA progression on enzalutamide did not prolong progression-free survival (5.7 vs 5.6 months; HR, 0.83; 95% CI, 0.61 to 1.12).
- In the control arms of randomized trials, median rPFS with a second ARPI was 3.7 months in CARD (after docetaxel), 3.6 months in PROfound cohort A (homologous recombination repair gene alterations), 4.5 months in the TRITON3 BRCA subgroup, and 5.59 months in PSMAfore (taxane-naive, third data cut-off), where 17% had a confirmed PSA decline of at least 50%. These figures are cross-trial. The PSMAfore investigators stated that a change in ARPI “has lesser clinical efficacy than taxanes”.
- Second ARPIs are nonetheless common in practice. In Medicare claims, novel hormonal therapy followed by a different novel hormonal therapy was the most common first- to second-line sequence (33%), only 28% of men starting first-line novel hormonal therapy later received a different class, and 22% received no life-prolonging therapy after mCRPC diagnosis.
- Taxane chemotherapy carries toxicity: the cabazitaxel label reports serious adverse reactions in 39% of recipients and neutropenic deaths, and in CARD treatment discontinuations for adverse reactions occurred in 20% of cabazitaxel recipients and 8% of those receiving abiraterone or enzalutamide. In TROPIC, grade 3 or higher neutropenia occurred in 82% of cabazitaxel recipients.
- PSMA-targeted radioligand therapy requires PSMA-positive disease on PET imaging and delivery by providers licensed to handle radiopharmaceuticals; in VISION, 126 screened participants (12.6%) did not meet PSMA imaging criteria. In PSMAfore, median overall survival was 24.5 months with lutetium Lu 177 vipivotide tetraxetan and 23.1 months with a change in ARPI (HR, 0.91; 95% CI, 0.72 to 1.14); the publication reported crossover in 134 of 234 participants (57%) randomized to ARPI change, which “may have confounded” the overall survival analysis, and the label reports crossover in 141 participants (60%).
- Biomarker-directed therapies apply to subsets. Alterations in BRCA2, BRCA1, or ATM were found in 29 of 150 metastatic biopsies (19.3%), rucaparib is labeled only for BRCA-mutated disease, and in the TRITON3 ATM subgroup the rPFS hazard ratio was 0.95 (95% CI, 0.59 to 1.52). First-line PARP inhibitor combinations are recommended only for patients who did not previously receive an ARPI, and the olaparib-abiraterone trial excluded prior abiraterone. Microsatellite instability-high or mismatch repair-deficient disease was found in 32 of 1033 patients (3.1%); pembrolizumab produced a response in 1 of 8 patients with prostate cancer in the tumor-agnostic label, and objective response rates of 5% and 3% in PD-L1-positive and PD-L1-negative cohorts after docetaxel and endocrine therapy.
- Other options have restricted populations: radium-223 is labeled for symptomatic bone metastases without known visceral disease, is not recommended with abiraterone plus prednisone because of more fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%), and caused bone marrow failure or ongoing pancytopenia in 2% of recipients. The sipuleucel-T trial excluded visceral metastases and moderate to severe cancer pain; each of its 3 doses requires leukapheresis, and it did not significantly prolong time to disease progression in any phase 3 study. Bisphosphonates have shown no survival benefit in any prospective trial, and overall survival was similar with denosumab and zoledronic acid.

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment); [Khalaf et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31727538/); [de Bono et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28844372/); [Attard et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6118405/); [de Wit et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31566937/); [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf); [Fizazi et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10064172/); [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/); [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/); [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf); [de Bono et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20888992/); [Sartor et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446332/); [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf); [Robinson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4484602/); [Rubraca prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf); [Abida et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6459218/); [Keytruda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Antonarakis et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7186583/); [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf); [Provenge prescribing information](https://www.fda.gov/media/78511/download); [Xgeva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125320s225lbl.pdf)

<a id="topic-2.2.2.1.10-2"></a>

### Progression on available treatments

> “All patients who receive treatment for mCRPC will eventually progress.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.10-3"></a>

### Cross-resistance between androgen receptor pathway inhibitors

> “In general, sequencing of ARPIs like abiraterone and enzalutamide is not recommended particularly if the time of response to ADT and to the first ARPI was short (≤ six to twelve months) and high-risk features of rapid progression are present”
> “Avoid sequencing of androgen receptor-targeted agents.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.10-4"></a>

### Radiographic progression-free survival with a change in ARPI

> “A change in ARPI has lesser clinical efficacy than taxanes,”
> “median rPFS in the ARPI change group was 5·59 months at third data cut-off”

Source: [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/)

<a id="topic-2.2.2.1.10-5"></a>

### Use of sequential ARPI therapy in place of chemotherapy

> “However, real-world data indicates that many patients do not receive taxane-based chemotherapy after progression on a first ARPI and instead switch to a second ARPI.”

Source: [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/)

> “The most common 1 L to 2 L treatment sequences among men with ≥2 lines were NHT followed by a different NHT (33%), chemotherapy followed by NHT (14%), and NHT followed by chemotherapy (13%).”
> “For those initiating 1 L treatment with NHTs, only 28% received subsequent treatment with a different class of therapy.”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-2.2.2.1.10-6"></a>

### Toxicity of taxane chemotherapy after ARPI

> “Neutropenic deaths have been reported.”
> “Serious adverse reactions occurred in 39% of patients receiving JEVTANA.”
> “Treatment discontinuations due to adverse drug reactions occurred in 20% of patients who received JEVTANA and 8% of patients who received abiraterone acetate plus prednisone/prednisolone or enzalutamide.”

Source: [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf)

<a id="topic-2.2.2.1.10-7"></a>

### Eligibility and delivery requirements for PSMA-targeted radioligand therapy

> “The eligibility criteria for PSMA imaging were not met in 126 patients (12.6%; those with no PSMA-positive lesions or ≥1 exclusionary PSMA-negative lesion) and were met in 869 patients (86.6%; those with ≥1 PSMA-positive lesion and no exclusionary PSMA-negative lesions);”

Source: [Sartor et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446332/)

> “Radiopharmaceuticals, including PLUVICTO, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.”

Source: [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)

<a id="topic-2.2.2.1.10-8"></a>

### Overall survival with radioligand therapy before taxane chemotherapy

> “The high crossover rate (134/234 patients [57%] randomised to ARPI change) may have confounded the analysis of overall survival.”

Source: [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/)

<a id="topic-2.2.2.1.10-9"></a>

### Eligibility for homologous recombination repair-directed therapy

> “If aberrations of BRCA2, BRCA1 and ATM all confer enhanced sensitivity to PARP inhibitors, 29/150 (19.3%) of mCRPC affected individuals would be predicted to benefit from this therapy.”

Source: [Robinson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4484602/)

<a id="topic-2.2.2.1.10-10"></a>

### Eligibility for checkpoint inhibitor therapy

> “The microsatellite instability–high/mismatch repair deficient phenotype is uncommon but clinically important in prostate cancer and can be somatically acquired during disease evolution.”

Source: [Abida et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6459218/)

<a id="topic-2.2.2.1.10-11"></a>

### Undertreatment in routine practice

> “22% received no life-prolonging therapy after mCRPC, 78% received ≥1 line of therapy (LOT), 42% underwent ≥2 LOTs, and 20% had ≥3 LOTs.”
> “These data highlight the dramatic undertreatment that occurs for mCRPC patients, particularly for therapies beyond NHTs as well as the common use of sequential NHTs in real-world data.”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

Additional sources: [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/); [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
